bovnews1h
Verve Therapeutics Inc (VERV) Stock’s 0.05% Increase This Year: What’s the Story?
Verve Therapeutics Inc (VERV) stock saw a modest uptick, ending the day at $6.57 which represents a slight increase of $0.43 or 7.00% from the prior close of $6.14. The stock opened at $6.25 and ...
bovnews2h
BigBear.ai Holdings Inc (BBAI) Stock Settles at $4.41: What’s Contributing to This Price Point?
BigBear.ai Holdings Inc (BBAI) stock saw a modest uptick, ending the day at $4.41 which represents a slight increase of $0.49 or 12.50% from the prior close of $3.92. The stock opened at $3.94 and ...
Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...
Vanda Pharmaceuticals (NASDAQ:VNDA) Given Buy Rating at HC Wainwright
HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report released on Tuesday,Benzinga reports. They currently have a $18.00 price ...
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $42.00 ...
H.C. Wainwright Reiterates Buy Rating on Axsome Shares
H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...
H.C. Wainwright Keeps Their Buy Rating on Disc Medicine (IRON)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine (IRON – Research Report) today and set a price target of $118.00.
Hosted on MSN11d
HC Wainwright & Co. Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation
Fintel reports that on January 10, 2025, HC Wainwright & Co. initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) ...
Nasdaq14d
H.C. Wainwright ups Sana target after ‘best case scenario’ data
H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...
Investing15d
H.C. Wainwright reiterates Neutral rating on CytomX post restructuring announcement
On Tuesday, H.C. Wainwright analysts maintained a Neutral rating on CytomX Therapeutics (NASDAQ:CTMX) following the company's announcement of a corporate restructuring and the prioritization of ...
Insider Monkey21d
BigBear.ai Holdings, Inc. (BBAI): H.C. Wainwright Boosts Price Target to $7, Citing AI Demand and Improved Financial Position
On December 30, H.C. Wainwright analyst Scott Buck raised the firm’s price target on BigBear.ai to $7 from $3 and kept a “Buy” rating on the shares. The analysts told investors in a research ...
Yahoo Finance26d
Palvella Therapeutics initiated with a Buy at H.C. Wainwright
https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-10-from-12-at-bofa H.C. Wainwright initiated coverage of Palvella Therapeutics ...